A combined model of serum neutrophil extracellular traps, CD8+ T cells, and tumor proportion score provides better prediction of PD‐1 inhibitor efficacy in patients with NSCLC

Abstract

Immune checkpoint inhibitors provide a definite survival benefit for patients with driver‐negative advanced non‐small cell lung cancer (NSCLC), but predictors of efficacy are still lacking. There may be a relationship between immune inflammatory state and tumor immune response. We explored the relationship of serum neutrophil extracellular traps (NETs) with infiltrating cells in the tumor tissues of patients with NSCLC as well as their relationship with the therapeutic efficacy of programmed cell death protein 1 (PD‐1) inhibitors. Serum myeloperoxidase (MPO)‐double‐stranded DNA (dsDNA) was detected as a marker of NET serum concentration. T cells were detected by immunohistochemical staining, and neutrophils were counted by MPO immunofluorescence staining. Of the 31 patients with NSCLC, a longer progression‐free survival after PD‐1 inhibitor treatment was associated with higher levels of CD3+ T cells, a lower neutrophil : CD3+‐T‐cell ratio (NEU/CD3+) and lower neutrophil : CD8+‐T‐cell ratio (NEU/CD8+) in tumor tissues. Patients with higher serum NETs were more likely to develop progressive disease after treatment (P = 0.003) and to have immune‐related adverse events (IrAEs) as well as higher NEU/CD3+ and NEU/CD8+. The combined model of serum NETs, CD8+ T cells, and tumor proportion score (TPS) significantly improved the prediction of PD‐1 inhibitor efficacy [P = 0.033; area under the curve (AUC) = 0.881]. Our results indicate that serum NETs are effective predictors of PD‐1 inhibitor response and reflect the tissue neutrophil‐to‐lymphocyte ratio and IrAE levels. The combined model of serum NETs, CD8+ T cells, and TPS is a powerful tool for predicting the efficacy of PD‐1 inhibitor treatment in patients with NSCLC.